IL241295A0 - Multifunctional quinoline derivatives as anti-neurodegenerative agents - Google Patents

Multifunctional quinoline derivatives as anti-neurodegenerative agents

Info

Publication number
IL241295A0
IL241295A0 IL241295A IL24129515A IL241295A0 IL 241295 A0 IL241295 A0 IL 241295A0 IL 241295 A IL241295 A IL 241295A IL 24129515 A IL24129515 A IL 24129515A IL 241295 A0 IL241295 A0 IL 241295A0
Authority
IL
Israel
Prior art keywords
multifunctional
quinoline derivatives
neurodegenerative agents
neurodegenerative
agents
Prior art date
Application number
IL241295A
Other languages
Hebrew (he)
Original Assignee
Annji Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annji Pharm Co Ltd filed Critical Annji Pharm Co Ltd
Publication of IL241295A0 publication Critical patent/IL241295A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
IL241295A 2013-04-02 2015-09-08 Multifunctional quinoline derivatives as anti-neurodegenerative agents IL241295A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/034960 WO2014163622A1 (en) 2013-04-02 2013-04-02 Multifunctional quinoline derivatives as anti-neurodegenerative agents

Publications (1)

Publication Number Publication Date
IL241295A0 true IL241295A0 (en) 2015-11-30

Family

ID=51658752

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241295A IL241295A0 (en) 2013-04-02 2015-09-08 Multifunctional quinoline derivatives as anti-neurodegenerative agents

Country Status (9)

Country Link
EP (1) EP2981525A4 (en)
JP (1) JP6153179B2 (en)
KR (1) KR101802048B1 (en)
CN (1) CN105452224B (en)
AU (1) AU2013385618B2 (en)
BR (1) BR112015024472A2 (en)
IL (1) IL241295A0 (en)
RU (1) RU2642466C2 (en)
WO (1) WO2014163622A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101725326B1 (en) * 2015-04-23 2017-04-12 대한민국 A novel isolated midroorganism having antibiotic activity and a production method of pseudane using the same
CN105949120B (en) * 2016-05-27 2018-07-24 广东工业大学 A kind of application of four teeth chelating type list quinoline and preparation method thereof and metal ion control agent as neurodegenerative disease
KR102281647B1 (en) * 2020-12-09 2021-07-30 메디케어제약 주식회사 Method of producing a derivative-piperazine
CN113527200B (en) * 2021-05-27 2022-12-02 北京斯利安药业有限公司 Preparation method of cloquinadol

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3682927A (en) * 1968-06-15 1972-08-08 Massimo Carissimi 5,7-bichloro-8-hydroxy-2-acetylamino quinoline
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
HUT71895A (en) * 1992-10-27 1996-02-28 Janssen Pharmaceutica Nv 4-quinolinyl derivatives with anti-helicobacter activity, pharmaceutical compositions containing them and process for producing them
EP0959888B1 (en) * 1996-08-13 2001-09-05 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
DE69827233T2 (en) * 1997-07-07 2005-03-24 Kowa Co., Ltd., Nagoya DIAMIDE DERIVATIVES AND MEDICAMENTS CONTAINING THEREOF
FR2819507B1 (en) * 2001-01-17 2007-09-28 Inst Rech Developpement Ird SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS
TWI268928B (en) 2002-03-27 2006-12-21 Glaxo Group Ltd Novel quinoline compounds, the processes for their preparation, the compositions containing them and their uses as medicaments
KR100557020B1 (en) 2002-04-30 2006-03-03 영진약품공업주식회사 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
CA2516842A1 (en) * 2003-02-25 2004-09-10 Topotarget Uk Limited Hydroxamic acid compounds comprising a bicylic heteroaryl group as hdac inhibitors
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
WO2005035534A1 (en) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
FR2889525A1 (en) * 2005-08-04 2007-02-09 Palumed Sa NOVEL POLYQUINOLINE DERIVATIVES AND THEIR THERAPEUTIC USE.
EP2079699A1 (en) * 2006-07-25 2009-07-22 Envivo Pharmaceuticals, Inc. Quinoline derivatives
EP2350012B1 (en) * 2008-10-06 2017-06-28 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
EP2576540B1 (en) * 2010-05-26 2019-09-04 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN102526052B (en) * 2012-01-19 2013-10-09 华南师范大学 Application of 2-gylcosyl chinoline compound in preparing acetylcholine esterase resisting medicines

Also Published As

Publication number Publication date
BR112015024472A2 (en) 2017-07-18
KR101802048B1 (en) 2017-12-28
RU2015137621A (en) 2017-05-11
EP2981525A4 (en) 2016-12-21
AU2013385618A1 (en) 2015-09-24
JP2016515617A (en) 2016-05-30
AU2013385618B2 (en) 2017-01-05
RU2642466C2 (en) 2018-01-25
JP6153179B2 (en) 2017-06-28
EP2981525A1 (en) 2016-02-10
WO2014163622A8 (en) 2014-11-13
WO2014163622A1 (en) 2014-10-09
CN105452224B (en) 2017-12-26
KR20150136070A (en) 2015-12-04
CN105452224A (en) 2016-03-30

Similar Documents

Publication Publication Date Title
HK1219735A1 (en) Quinoline derivative
ZA201506880B (en) Quinolines derivatives as novel anticancer agents
HK1215795A1 (en) Amatoxin derivatives
SG11201505309TA (en) Benzylamine derivatives
LT2953944T (en) Pyridazinone-amides derivatives
HK1215574A1 (en) Diazacarbazole derivatives as tau-pet-ligands tau-pet-
LT3027598T (en) Oxoquinazolinyl-butanamide derivatives
HK1213484A1 (en) Neurogenesis-stimulating isoquinoline derivatives
PL3087076T3 (en) Imidazopyrazinone derivatives
EP2966074A4 (en) Morphinan derivative
IL241295A0 (en) Multifunctional quinoline derivatives as anti-neurodegenerative agents
HK1216099A1 (en) Benzylamine derivatives
HK1213566A1 (en) Novel tetrazolone derivatives
GB201300649D0 (en) Cyclization
GB201314960D0 (en) Heterocyclic derivatives
GB201300306D0 (en) Heterocyclic derivatives